Why the Independent Panel Just Overrode the FDA on Peptides

Hearings & news coverage — Why the Independent Panel Just Overrode the FDA on Peptides

Channel: Modern Healthspan · Our label: Hearing coverage and news reporting · Source: youtube.com/watch?v=1_RpuwcGiuc

What this video covers

and laying A regulatory event has just transformed the future of peptide therapy and longevity medicine in the United States. For the past 3 years, clinicians, researchers, and patients interested in using peptides have faced severe restrictions. This decision created widespread disruption across the health and community, leaving thousands of patients with limited access to therapies that they had relied on for tissue repair, gut health, and metabolic optimization. However, following major policy shifts within Department of Health and Human Services in…

Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.

Key points, in the speaker’s own framing

• This decision created widespread disruption across the health and community, leaving thousands of patients with limited access to therapies that they had relied on for tissue repair, gut health, and metabolic optimization.
• Traditional compounding pharmacies prepare customized medications prescribed by licensed physicians for individual patients whose medical needs cannot be met by commercially manufactured FDA-approved drugs.
• They were BPC 157, a 15 amino acid synthetic peptide derived from human gastric juices, evaluated for ulcerative colitis and inflammatory tissue repair.
• KPV, a tripeptide fragment derived from alpha melanocyte stimulating hormone, evaluated for wound healing and gastrointestinal inflammation.
• And the last approved peptide was Epitalon, a synthetic tetrapeptide modeled after the pineal bioregulator epithalamin, widely studied in longevity science for its role in cellular health and telomerase activation.
• If placed in category 1, the FDA would exercise enforcement discretion, allowing compounding pharmacies to legally resume preparing these customized prescriptions right away while the formal rule making progresses.

Read next

• BPC-157 — compound page
• TB-500 — compound page
• MOTS-c — compound page
• KPV — compound page
• All videos from this channel

Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.